Although inducing apoptosis has been a focus for boosting cancer treatment and polymorphisms in MCL-1 [13] and BCL-2 [14] are associated with susceptibility to TB disease, we were the first to interrogate inducing apoptosis through targeted inhibition of the anti-apoptotic BCL-2 proteins (specifically, MCL-1) for TB treatment [15]. Here, BCL2 is linked to cancer.